We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK’s NICE Weighs In on Cardiac Therapies, Recommends Novel Migraine Treatment
UK’s NICE Weighs In on Cardiac Therapies, Recommends Novel Migraine Treatment
The UK’s healthcare cost-benefit watchdog is recommending implantable cardioverter defibrillators as a first-line treatment for people with previous serious ventricular arrhythmia, those with a familial cardiac condition with a high risk of sudden death and patients who have undergone surgical repair of congenital heart disease.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor